Abstract
Type 1 diabetes mellitus is an autoimmune disease that is characterized by the destruction of the islets of Langerhans cells which produce insulin. The current gold standard treatment is exogenous insulin injection, but this is onerous for the patients, and can lead to severe complications. Another approach involves transplanting pancreatic islet cells in order to restore endogenous insulin production under physiologic regulation. Although there has been some success with this treatment plan, there have been several hurdles. The largest hurdle is improving the 5 year survival of the graft, which is currently at 10%. In order to do so, there has been research into better locations for the graft, better isolation techniques, alternate immune suppression regimens, and novel transplantation methodologies utilizing encapsulated grafts. Another hurdle for pancreatic islet transplantation is that current methodologies require islets from several pancreata in order to create one successful graft, which leads to difficulties since there is a limited supply. However, there has been research looking into single donor transplants and porcine xenografts to increase the supply and address this problem. In this article, we review the current state of research regarding pancreatic islet transplantation.
Keywords: Autoimmunity, Type 1 diabetes, Immune rejection, Islet transplantation, Pancreas transplantation.
Current Diabetes Reviews
Title:Pancreatic Islet Transplantation in Type 1 Diabetes Mellitus: An Update on Recent Developments
Volume: 9 Issue: 4
Author(s): Arjun Ramesh, Preeti Chhabra and Kenneth L. Brayman
Affiliation:
Keywords: Autoimmunity, Type 1 diabetes, Immune rejection, Islet transplantation, Pancreas transplantation.
Abstract: Type 1 diabetes mellitus is an autoimmune disease that is characterized by the destruction of the islets of Langerhans cells which produce insulin. The current gold standard treatment is exogenous insulin injection, but this is onerous for the patients, and can lead to severe complications. Another approach involves transplanting pancreatic islet cells in order to restore endogenous insulin production under physiologic regulation. Although there has been some success with this treatment plan, there have been several hurdles. The largest hurdle is improving the 5 year survival of the graft, which is currently at 10%. In order to do so, there has been research into better locations for the graft, better isolation techniques, alternate immune suppression regimens, and novel transplantation methodologies utilizing encapsulated grafts. Another hurdle for pancreatic islet transplantation is that current methodologies require islets from several pancreata in order to create one successful graft, which leads to difficulties since there is a limited supply. However, there has been research looking into single donor transplants and porcine xenografts to increase the supply and address this problem. In this article, we review the current state of research regarding pancreatic islet transplantation.
Export Options
About this article
Cite this article as:
Ramesh Arjun, Chhabra Preeti and Brayman L. Kenneth, Pancreatic Islet Transplantation in Type 1 Diabetes Mellitus: An Update on Recent Developments, Current Diabetes Reviews 2013; 9 (4) . https://dx.doi.org/10.2174/15733998113099990063
DOI https://dx.doi.org/10.2174/15733998113099990063 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Characteristics and Outcomes of Children with Type-I Diabetes Mellitus Hospitalized for Ketoacidosis
Current Diabetes Reviews Curcumin and its Multi-target Function Against Pain and Inflammation: An Update of Pre-clinical Data
Current Drug Targets Vulnerable Atherosclerotic Plaque: Clinical Implications
Current Vascular Pharmacology Prevalence and Risk Factors for Diabetes Mellitus in A State in South East Nigeria: Results of a Population Based House to House Survey
Current Diabetes Reviews Antiviral and Virucidal Activities of Natural Products
Current Medicinal Chemistry TNF-α and Ghrelin: Opposite Effects on Immune System, Metabolism and Mental Health
Protein & Peptide Letters Advanced Therapies For End-Stage Heart Failure
Current Cardiology Reviews Peripheral Arterial Disease: The Magnitude of the Problem and its Socioeconomic Impact
Current Drug Targets - Cardiovascular & Hematological Disorders A Proteomic Approach To Porcine Saliva
Current Protein & Peptide Science Erectile Dysfunction as a Cardiovascular Risk Factor: Time to Step Up?
Current Vascular Pharmacology Selective Glucocorticoid Receptor Ligands
Medicinal Chemistry Why and How We Should Treat Elderly Patients with Hypertension?
Current Vascular Pharmacology Diagnosis and Management of Diabetes and the Relationship of dGlucose to Kidney Function
Current Diabetes Reviews Neuroprotection by Resveratrol in Diabetic Neuropathy: Concepts & Mechanisms
Current Medicinal Chemistry Transient Receptor Potential A1 Modulators
Current Topics in Medicinal Chemistry Oxidative Stress Signaling in Alzheimers Disease
Current Alzheimer Research Gram-scale Synthesis of a Novel Core Building Block for the New GPR40 Agonist Design
Letters in Organic Chemistry The Antioxidant Effects of Radix Astragali (Astragalus membranaceus and Related Species) in Protecting Tissues from Injury and Disease
Current Drug Targets Personalized Drug Therapy in Cystic Fibrosis: From Fiction to Reality
Current Drug Targets Pharmacogenetics of the Glucagon-like Peptide-1 Receptor Agonist Liraglutide: A Step Towards Personalized Type 2 Diabetes Management
Current Pharmaceutical Design